Michael Burke, MD
Medical Oncology · Hartford, CTNPI 1265829741
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $131 of the $173 with a category attached, or 75.7%. 8 manufacturers reported payments, led by Mirati Therapeutics, Inc. at 24.3% of the total. Reporting peaked in 2023 at $123 and has fallen 79.3% since, to $25 in 2024. That places this record below the midpoint for medical oncology clinicians in CT, where the typical reported total is $3,212.
Across 10 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mirati Therapeutics, Inc.$42
- Gilead$28
- Blue Earth Diagnostics$25
- Lilly USA, LLC$20
- Pfizer$16
- KCI USA, Inc.$15
- plus $26 from 2 others
What the payments were for
- Food & beverage$13176%
- Education$4224%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mirati Therapeutics, Inc. | 2 | $42 |
| Gilead | 2 | $28 |
| Blue Earth Diagnostics | 1 | $25 |
| Lilly USA, LLC | 1 | $20 |
| Pfizer | 1 | $16 |
| KCI USA, Inc. | 1 | $15 |
| Genmab U.S., Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
How this compares
$173 in reported general payments places this provider in the 25th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 20 | $23,084 |
| XareltoRivaroxaban | 11 | $8,953 |
| Anastrozole | 28 | $523 |
| Prochlorperazine Maleate | 30 | $478 |
| Ondansetron OdtOndansetron | 17 | $322 |
| LoperamideLoperamide Hcl | 30 | $308 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $236 |
| Dexamethasone | 11 | $203 |
| Oxycodone Hcl | 14 | $177 |
| Prednisone | 17 | $65 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $12 | $8,95311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 79 medical oncology providers in Connecticut.
Other medical oncology in Hartford
- Ira SuroliaHartford$3K
- Devendra KcHartford$189
- Peter MarksNew Haven$578K
- Daniel PetrylakNew Haven$446K
- Mandar MuzumdarNew Haven$371K
- Barbara BurtnessNew Haven$297K
- Ian KropNew Haven$219K
- Joseph McLaughlinManchester$200K
- Francine FossNew Haven$193K
- William OhGreenwich$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.